で公開中です! 詳しく見る
0.1557 USD
-0.0181
10.41%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
0.1622
+0.0065
4.17%
1日
-10.41%
5日間
-30.18%
1か月
-33.18%
3か月
-41.31%
6か月
-65.03%
年初来
-81.66%
1年
-91.15%
5年間
-95.9%
10年間
-97.22%
 

概要: Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.

従業員数: 809

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 0%
ニュートラル 100%
ネガティブ 0%
ニュートラル
PRNewsWire
10 日前
Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director
MADISON, Wis., Oct. 6, 2026 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) today announced that stockholders approved all proposals presented at the company's Special Meeting of Stockholders held on October 6, 2026, enabling Accuray to complete its previously announced transactions with TCW Asset Management Company LLC, the company's primary lender and largest shareholder.
Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director
ニュートラル
PRNewsWire
19 日前
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
MADISON, Wis., Sept. 27, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that it had entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp. ("Samsung NeuroLogica") to pursue advanced volumetric imaging capabilities for the CyberKnife® System.
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
ニュートラル
PRNewsWire
先月
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
MADISON, Wis., Sept. 11, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, and RaySearch Laboratories AB (publ) today announced that they had entered into a definitive agreement providing for an expanded collaboration aimed at accelerating Accuray's adoption of online adaptive radiation therapy.
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
ニュートラル
Seeking Alpha
先月
Accuray Incorporated (ARAY) Q4 2026 Earnings Call Transcript
Accuray Incorporated (ARAY) Q4 2026 Earnings Call Transcript
Accuray Incorporated (ARAY) Q4 2026 Earnings Call Transcript
ニュートラル
PRNewsWire
先月
Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results
MADISON, Wis., Aug. 19, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2026, ended June 30, 2026.
Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results
ニュートラル
PRNewsWire
2 か月前
Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments
MADISON, Wis., Aug. 12, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced two key leadership appointments intended to improve operational execution and profitability, deliver increased customer value, and enhance overall enterprise performance as the company continues to advance the strategic priorities in its recently announced transformation plan focused on sustainable, profitable growth.
Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments
ニュートラル
PRNewsWire
2 か月前
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
MADISON, Wis., Aug. 5, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2026, ended June 30, 2026, during a conference call hosted by company management at 1:30 p.m.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
ニュートラル
PRNewsWire
2 か月前
Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation
MADISON, Wis., July 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced a plan incorporating several decisive actions that will drive a significant improvement in its financial position, a fundamental change in its business strategy, the rollout of differentiated technology, and continued transformation in how the company operates.
Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation
ニュートラル
PRNewsWire
4 か月前
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
MADISON, Wis., May 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Commercial Officer and David Shin, the company's new Chief Legal Officer.
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
ニュートラル
PRNewsWire
5 か月前
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
MADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform.
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
価格チャートは Lightweight Charts™ を使用して実装されています